Brain Tumor Center, New York, NY, USA.
Ann Neurol. 2011 Jul;70(1):163-9. doi: 10.1002/ana.22360. Epub 2011 Mar 9.
To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL).
In this prospective longitudinal study, serum samples from consecutive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonance imaging (MRI) scans at multiple time points and were analyzed for levels of YKL-40 and MMP-9 by enzyme-linked immunosorbent assay. Marker levels were correlated to disease status and survival.
Forty-five patients with PCNSL were accrued. Median follow-up for survivors was 25 months, and 21 (47%) died during the study. A total of 230 serum samples were collected, and 93% had corresponding MRI scans. PCNSL patients without evidence of radiographic disease (29 patients, 131 samples) had significantly lower levels of serum YKL-40 and MMP-9 than patients with active tumor (n = 34 patients, 84 samples; p = 0.03 and 0.01, respectively). There was a significant inverse correlation between survival and doubling of the YKL-40 level (hazard ratio, 1.7; p = 0.01).
In patients with PCNSL, serum levels of YKL-40 and MMP-9 are associated with radiographic disease status. Longitudinal increase in serum levels of YKL-40, but not MMP-9, predicts survival in patients with PCNSL.
评估 YKL-40 和 MMP-9 蛋白作为原发性中枢神经系统淋巴瘤（PCNSL）患者血清样本中的肿瘤标志物。
在这项前瞻性纵向研究中，连续收集经组织学证实的 PCNSL 患者的血清样本，并在多个时间点进行磁共振成像（MRI）扫描，通过酶联免疫吸附试验分析 YKL-40 和 MMP-9 的水平。标志物水平与疾病状态和生存相关。
共纳入 45 例 PCNSL 患者。幸存者的中位随访时间为 25 个月，研究期间有 21 例（47%）死亡。共采集了 230 份血清样本，其中 93%有相应的 MRI 扫描。无影像学疾病证据的 PCNSL 患者（29 例，131 份样本）的血清 YKL-40 和 MMP-9 水平明显低于有活动性肿瘤的患者（n = 34 例，84 份样本；p = 0.03 和 0.01）。YKL-40 水平翻倍与生存呈显著负相关（危险比，1.7；p = 0.01）。
在 PCNSL 患者中，血清 YKL-40 和 MMP-9 水平与影像学疾病状态相关。YKL-40 血清水平的纵向升高，但不是 MMP-9，可预测 PCNSL 患者的生存。
